Novartis' new cell therapy facility could ease manufacturing squeeze for CAR-T med Kymriah

Novartis' new facility will eventually employ 450 workers. (Novartis)

Novartis' big push into cell and gene therapy hasn't been the smoothest of rides, with a data manipulation scandal hamstringing Zolgensma and manufacturing concerns hurting CAR-T cancer therapy Kymriah. Could a new European facility help turn around the latter's production bottleneck? 

Novartis last week opened its newest cell and gene therapy facility in Stein, Switzerland, giving the drugmaker a closer-to-home option for Kymriah patients, the company said in a release.

The new facility, which is expected to employ 450 workers, will allow Novartis to manufacture tailored cell therapies for European patients, opening a bottleneck that previously required two transatlantic flights to the drugmaker's sole facility in Morris Plains, New Jersey. 


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

“Our site in Stein is vital for new launches of solid and liquid drugs,” Steffen Lang, Novartis' global head of technical operations, said in a release. "The construction of the new manufacturing facility is another investment in the production of breakthrough cell-based therapies that can potentially change the lives of patients.”

Novartis said Kymriah will face a European regulatory decision in early 2020, which would immediately open the facility for commercial production.

RELATED: Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask

The Stein plant currently employs 185 employees, many of whom previously worked at Novartis' "traditional chemical and pharmaceutical manufacturing" sites in Basel, Schweizerhalle and Stein. 

"The importance of this traditional production is diminishing, as the portfolio trend is increasingly toward small-volume, difficult-to-manufacture and highly complex products," the company said in a release. 

In all, Novartis plans to employ 450 workers at the Stein facility at a CHF 90 million ($90.6 million) investment over three years. 

Ever since Kymriah's initial FDA approval in late 2017, the expensive and difficult-to-manufacture cancer therapy has given Novartis headaches despite blockbuster sales hopes. 

The manufacturing process for Kymriah is very complex, requiring that blood be taken from a patient, cryopreserved, shipped to a manufacturing facility, reprogrammed and manufactured in the lab, and then shipped back for infusion into the patient, all in the shortest time possible to try to outrun aggressive cancers.

Adding to the logistical nightmares, the manufacturing process itself has had issues staying within commercial spec since Kymriah's approval. 

In December 2018, Novartis acknowledged that it was providing doses of Kymriah manufactured out of spec at no cost for physicians seeking last-ditch solutions for patients with aggressive and hard-to-treat cancers. Liz Barrett, then-CEO of Novartis Oncology, outlined in early 2018 there was an issue around cell variability when treating relapsed large B-cell lymphoma that involved the number of inactive cells, which has sometimes resulted in the drug being out of line from the commercial specs.

Despite those challenges, Kymriah's growing demand is still driving up the therapy's sales. In the third quarter, Kymriah hit $79 million worldwide, a 295% increase from the same time last year. 

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.